Lu C., Qin F., Yan Y. et al. (2017) Immunosupressive treatment
for myocarditis: a meta-analysis of randomized controlled trials. J. Car-
diovasc. Med., Vol. 17: 631–637. DOI: 10.2459/jcm.0000000000000134.
50.
Lu M., Samblanet K., Roberts C. (2020) Myocarditis: A Heart
on Fire. Curr. Sports Med. Rep., Vol. 19(3): 110–112. doi: 10.1249/
JSR.0000000000000698.
51.
Mahrholdt H., Greuilich S. (2017) Prognosis in myocarditis.
J. Am. Col. Cardiol., Vol. 70: 1988–1990. doi: 10.1016/j.jacc.2017.08.062.
52.
Maisch B. (2019) Cardio-Immunology of Myocarditis: Focus
on Immune Mechanisms and Treatment Options. Frontiers in Cardiovas-
cular Medicine, Vol. 6: 48. doi: 10.3389/fcvm.2019.00048.
53.
Maisch B., Alter P. (2018) Treatment options in myocarditis
and inflammatory cardiomyopathy: focus on i. v. immunoglobulins. Herz,
Vol. 43(5): 423–430. doi: 10.1007/s00059–018–4719-x.
54.
Maisch B., Ristic A.D., Pankuweit S. (2017) Inflammato-
ry cardiomyopathy and myocarditis. Herz, Vol. 42(4): 425–438. doi:
10.1007/s00059–017–4569-y.
55.
Massilamany C., Huber S.A., Cunningham M.W. et al. (2014) Relevance of molecular mimicry in the mediation of infectious
myocarditis. J. Cardiovasc. Trans Res., Vol. 7(2): 165–71. doi: 10.1007/
s12265–013–9519–3.
56.
Merken J., Hazebroek M., Van Paassen P. et al. (2018) Im-
munosuppressive Therapy Improves Both Short- and Long-Term Progno-
sis in Patients With Virus Negative Nonfulminant Inflammatory Cardio-
myopathy. Circulation: Heart Failure, Vol. 11: e004228. DOI: 10.1161/
CIRCHEARTFAILURE.117.004228.
57.
Nensa F., Kloth J., Tezgah E. et al. (2016) Feasibility of FDG-
PET in myocarditis: Comparison to CMR using integrated PET/MRI.
J. Nucl. Cardiol., Vol. 25: 616– 624. doi: 10.1007/s12350–016–0616-y.
58.
